Mostrar el registro sencillo del ítem

dc.contributor.authorRodríguez-Cobos, Javier
dc.contributor.authorViñal, David
dc.contributor.authorPoves, Carmen
dc.contributor.authorFernández-Aceñero, María J.
dc.contributor.authorPeinado Selgas, Hector 
dc.contributor.authorPastor-Morate, Daniel
dc.contributor.authorPrieto, Mª Isabel
dc.contributor.authorBarderas Manchado, Rodrigo 
dc.contributor.authorRodríguez-Salas, Nuria
dc.contributor.authorDomínguez, Gemma
dc.date.accessioned2021-05-24T16:57:02Z
dc.date.available2021-05-24T16:57:02Z
dc.date.issued2021-05
dc.identifier.citationCancers (Basel). 2021 May; 13(9): 2240.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/13009
dc.description.abstractThe early diagnosis of colorectal cancer is a key factor in the overall survival of the patients. The actual screening programs include different approaches with significant limitations such as unspecificity, high invasiveness, and detection at late stages of the disease. The specific content of extracellular vesicles derived from malignant cells may represent a non-invasive technique for the early detection of colorectal cancer. Here, we studied the mRNA levels of ∆Np73, TAp73, and ∆133p53 in plasma-derived extracellular vesicles from healthy subjects (n = 29), individuals with premalignant lesions (n = 49), and colorectal cancer patients (n = 42). Extracellular vesicles’ ∆Np73 levels were already significantly high in subjects with premalignant lesions. ∆133p53 levels were statistically increased in colorectal cancer patients compared to the other two groups and were associated with patients’ survival. Remarkably, TAp73 mRNA was not detected in any of the individuals. The evaluation of ∆Np73, ∆133p53 and CEA sensitivity, specificity and AUC values supports ∆Np73 as a better early diagnosis biomarker and CEA as the best to identify advanced stages. Thus, low levels of CEA and a high content of ∆Np73 may identify in screening programs those individuals at higher risk of presenting a premalignant lesion. In addition, ∆133p53 emerges as a potential prognosis biomarker in colorectal cancer.es_ES
dc.description.sponsorshipThis work was supported by PI18/00473 (ISCIII, Ministry of Economy and Competitiveness and co-funded with FEDER funds) and PI17CIII/00045 research project from AES-ISCIII.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.uriAn error occurred getting the license - uri.*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectΔNp73es_ES
dc.subjectTAp73es_ES
dc.subjectΔ133p53es_ES
dc.subjectColorectal canceres_ES
dc.subjectExtracellular vesicleses_ES
dc.subjectLiquid biopsyes_ES
dc.subjectScreening programses_ES
dc.subjectBiomarkerses_ES
dc.subjectEarly diagnosises_ES
dc.subjectPremalignant lesionses_ES
dc.titleΔNp73, TAp73 and Δ133p53 Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Canceres_ES
dc.typejournal articlees_ES
dc.rights.licenseAn error occurred on the license name.*
dc.rights.licenseAtribución 4.0 Internacional*
dc.format.volume13es_ES
dc.format.number9es_ES
dc.format.page2240es_ES
dc.identifier.doi10.3390/cancers13092240es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2072-6694es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/cancers13092240es_ES
dc.identifier.journalCancerses_ES
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI18/00473es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17CIII/00045es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem